LINC02418 upregulates EPHA2 by competitively sponging miR-372-3p to promote 5-Fu/DDP chemoresistance in colorectal cancer

Yao, Fei; Huang, Xiaoying; Xie, Zhufu; Chen, Jie; Zhang, Ling; Wang, Qiang; Long, Hui; Jiang, Jue; Wu, Qingming

doi:10.1093/carcin/bgac065

Cited by 6 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 LINC02418 indirectly regulates EPHA2 by targeting miR-372-3p, which lays an important foundation for reducing the drug resistance of colorectal cancer cells and promoting the treatment of colorectal cancer. 12 However, the molecular regulatory mechanisms of lncRNAs in breast cancer remain unclear, so this study delves into the molecular regulation of key lncRNAs in breast cancer progression. The luciferase activity report indicates a targeted binding site between LINC02418 and miR-766-5p.…”

Section: Discussionmentioning

confidence: 99%

“… 11 In colorectal cancer, it was discovered that LINC02418 significantly contributes as a critical gene in the screening of chemotherapy-related ceRNA networks. 12 LINC02418 was found to be abnormally expressed in endometrial cancer and has the potential to be a biomarker for patient prognosis. 13 Recent studies have found that LINC02418 can affect the expression of PD-L1 in non-small cell lung cancer and participate in CD8+T cell infiltration.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression and Significance of LINC02418 in Breast Cancer

Zhou,

Huang

2024

BCTT

View full text Add to dashboard Cite

Purpose The complicated pathogenesis and poor prognosis of breast cancer have become a major difficulty in medical research. This study aims to explore new lncRNA as prognostic markers for breast cancer and explore their roles and molecular mechanisms to lay a foundation for the treatment of cancer patients. Patients and Methods The expression of LINC02418 and miR-766-5p in breast cancer tissues and cells was first identified using polymerase chain reaction, and Pearson was used to examine the correlation between the two. The cancer cells activities under different transfection conditions were detected using the Transwell assay and CCK8 assay. The correlation between LINC02418 and patient prognosis was analyzed using multifactor Cox regression and Kaplan-Meier. Results It was shown that LINC02418 expression was upregulated in breast cancer tissues and cells. There are significant differences in lymph node metastasis and TNM stage between high and low LINC02418 expression groups. The higher the expression of LINC02418, the higher the mortality rate of breast cancer patients. miR-766-5p expression was downregulated and negatively correlated with LINC02418. There are binding sites between LINC02418 and miR-766-5p; Transfection with miR-766-5p inhibitor boosted LINC02418 luciferase activity, but transfection with miR-766-5p mimic decreased it. Knockdown of LINC02418 promoted miR-766-5p expression and inhibited cancer progression, which was alleviated to some extent by transfection with miR-766-5p inhibitors. Conclusion LINC02418 has the potential to serve as a poor prognostic marker for breast cancer and plays a pro-oncogenic role by targeting miR-766-5p.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Expression and Significance of LINC02418 in Breast Cancer

Zhou,

Huang

2024

BCTT

View full text Add to dashboard Cite

show abstract

“…Notably, levels of miR-372-3p in the blood of HCC patients responsive to TACE with doxorubicin are significantly higher than those in nonresponders. In colorectal cancer, miR-372-3p interacts with LINC02418 to impact the effectiveness of 5-Fu chemoresistance [ 78 ].…”

Section: Genes Associated With Doxorubicin Resistancementioning

confidence: 99%

Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer

Huang

Wang

et al. 2023

Cells

View full text Add to dashboard Cite

Liver cancer is one of the most lethal cancers in the world, mainly owing to the lack of effective means for early monitoring and treatment. Accordingly, there is considerable research interest in various clinically applicable methods for addressing these unmet needs. At present, the most commonly used biomarker for the early diagnosis of liver cancer is alpha-fetoprotein (AFP), but AFP is sensitive to interference from other factors and cannot really be used as the basis for determining liver cancer. Treatment options in addition to liver surgery (resection, transplantation) include radiation therapy, chemotherapy, and targeted therapy. However, even more expensive targeted drug therapies have a limited impact on the clinical outcome of liver cancer. One of the big reasons is the rapid emergence of drug resistance. Therefore, in addition to finding effective biomarkers for early diagnosis, an important focus of current discussions is on how to effectively adjust and select drug strategies and guidelines for the treatment of liver cancer patients. In this review, we bring this thought process to the drug resistance problem faced by different treatment strategies, approaching it from the perspective of gene expression and molecular biology and the possibility of finding effective solutions.

show abstract

“…Moreover, additional functionalities of lncRNAs could be tested. For instance, studying the role of lncRNAs as miRNA sponges, as performed in other tumor types ( 13 - 15 ) would be an important next step in understanding how lncRNAs impact post-transcriptional regulation in pediatric cancers. In this context, the TARGET project database contains miRNA-seq data for all the studied cancer types except for NBL.…”

mentioning

confidence: 99%